RaySearch Laboratories AB: Accuray and RaySearch agree to collaboration integrating RayStation software with Accuray platforms to accelerate Accuray's online adaptive capabilities

RaySearch (STO: RAY B) and Accuray (NASDAQ: ARAY) agreed to expand their collaboration to accelerate online adaptive radiation therapy. Accuray will purchase RayStation licenses worth $8M, recognized as revenue in 2026. The partnership combines Accuray's platforms with RaySearch's software for personalized treatments.

Original reporting
Published Sep 11, 2026, 2:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 3:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$ARAY
Neutral
medium confidence
Mentioned
$ARAY
Relevance
6/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$ARAYNeutralLow
01

Why it matters

The collaboration could accelerate adoption of adaptive therapy, improving clinical workflow and creating a new revenue stream for both firms.

02

Market read

A modest $8 M deal that signals strategic alignment in the oncology tech space, with limited immediate price impact.

03

What to watch

Potential future revenue from expanded license sales and cross‑selling to existing RaySearch customers.

Relevance 6/10Novelty 6/10Timing: today

Background

Accuray and RaySearch are partnering to integrate RayStation planning software with Accuray's Radixact and future CyberKnife platforms for online adaptive radiation therapy.

Company-level read

Ticker impact

$ARAYNeutralMedium confidence
Context

Accuray announced a definitive agreement to purchase RayStation licenses worth $8 million, creating a new revenue stream in Q3‑Q4 2026.

Expected impact

Limited upside; price may edge higher on the news but unlikely to move sharply.

Evidence & confidence

The $8 M deal is small relative to Accuray's revenue, but it signals progress on online adaptive therapy, a strategic priority.

Market effects

Highlights growing demand for adaptive radiation therapy software in the med‑tech sector.

Swedish‑based RaySearch gains exposure; U.S. oncology equipment market sees incremental collaboration.

Modest; reinforces trend of software‑hardware integration in cancer treatment worldwide.

Counterpoint

The $8 M contract is too small to materially affect Accuray's valuation; investors may overlook it.

Key entities

  • Accuray Incorporated

    U.S. medical device maker developing radiation therapy platforms.

  • RaySearch Laboratories AB

    Swedish developer of oncology treatment planning software.

Related articles

Low

[SCHEDULE 13D/A] ACCURAY INC Amended Major Shareholder Report

Accuray Inc. amended a major shareholder report, detailing a $55M issuance of Series A Convertible Preferred Stock to investors, including affiliates of the reporting person. The deal involves $15M in cash and $40M in debt conversion, with warrants issued as incentives. The transaction is subject to closing conditions and stockholder approval. If not approved, a $15M fee is payable. The Series A Preferred Stock is convertible into common stock at $0.50 per share. TCW Asset Management gains board

$ARAYMed

Balance Sheet Rescue Meets China Drag in Accuray’s (ARAY) Mixed Quarter

Accuray (ARAY) reported a 21% revenue decline to $100.9M in Q4 2026, with China's market contributing to a 42% drop in product revenue. The company secured $60M in financing from TCW Asset Management, improving its balance sheet. Service revenue grew 6%, and cost savings exceeded targets. However, Accuray did not provide 2027 guidance due to trade policy uncertainties.

$ARAYHighAI 8/10

Accuray (ARAY) Q4 2026 Earnings Call Transcript

Accuray (ARAY) reported Q4 2026 revenue of $100.9M, down 21% YoY, with product revenue declining 42% due to geopolitical tensions. Service revenue grew 6% to $60.1M. Full-year revenue was $401.9M, down 12%. The company realized $20M in cost savings and expects $15M more in FY27. Adjusted EBITDA was $12.9M, up from $9.4M YoY. Management cited trade policy uncertainty and regional volatility as risks.

$ARAYMedAI 8/10

Accuray Incorporated Q4 2026 Earnings Call Summary

Accuray Incorporated reported Q4 2026 earnings, noting a $58M revenue decline due to China's geopolitical tensions. The company is shifting to a partner-centric model and saw 6% service revenue growth. Management highlighted clinical data validating their technology and $20M in cost improvements. No formal guidance was given for 2027 due to uncertainty. A debt-to-equity conversion with TCW and a reverse stock split plan were announced.

$ARAYHighAI 8/10

Accuray Inc (ARAY) (Q4 2026) Earnings Call Highlights: Strategic Transformation

Accuray Inc (ARAY) reported a 12% year-over-year revenue decline to $402M for fiscal 2026, with product revenue down 27% due to China sales drop. Gross margin fell to 27.7% from 32.1%, and operating loss was $26.4M. Management cited geopolitical tensions and tariff uncertainty. The company secured $55M in funding from TCW Asset Management, converting debt and receiving cash investment. Service revenue grew 4% year-over-year, and the company aims to improve cost structure and market reach in fisc